1
|
Atanasovska E, Jakjovski K, Pavlovska K, Gjorgjievska K, Zafirov D, Zendelovska D, Petrushevska M, Labachevski N. Comparative, Single-Dose, 2-Way Cross-Over Bioavailability Study of Two Olanzapine 10 Mg Tablet Formulations in Healthy Volunteers Under Fasting Conditions. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2022; 43:135-143. [PMID: 35843923 DOI: 10.2478/prilozi-2022-0026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objectives: Olanzapine is an atypical antipsychotic that is approved across Europe, the USA, and in many other countries for oral treatment of schizophrenia and acute manic episodes in patients with bipolar disorder as well as for maintenance therapy to prevent recurrence in responders. The objective of the present study was to compare the pharmacokinetics of two 10 mg tablet formulations of Olanzapine following a single oral dose in healthy volunteers under fasting conditions, as per the European Medicine Agency (EMA) guidelines to grant marketing authorization. Methods: This study was a randomized, open-label, two-treatment, two-period, two-sequences, single-dose, cross-over design with a washout period of 14 days. Both the test and the reference products were administered as 10 mg tablets with 240 mL of water after an overnight fast in each study period. A total of twenty blood samples were collected before dosing and within 144 hours after drug administration. Adverse events were monitored, recorded, and evaluated by investigators throughout the study. Results: Of the 24 healthy adult male subjects enrolled, all of them completed both study periods. The geometric mean ratio 90% confidence intervals (CI) for fasting Cmax, AUC0-t, and AUC0-infinity were 94.83-113.71%, 95.04-105.69% and 95.94-107.00%, respectively. The 90% CI for the ratios of the three primary pharmacokinetic parameters (using log-transformed data) were within the range of 80-125%, meeting the regulatory criteria for bioequivalence. Conclusions: The generic Olanzapine was bioequivalent to the reference formulation. It was well tolerated and provides an acceptable alternative to the reference drug.
Collapse
Affiliation(s)
- Emilija Atanasovska
- Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University "Ss. Cyril and Methodius", 50 Divizija 6, 1000 Skopje, Republic of North Macedonia
| | - Krume Jakjovski
- Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University "Ss. Cyril and Methodius", 50 Divizija 6, 1000 Skopje, Republic of North Macedonia
| | - Kristina Pavlovska
- Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University "Ss. Cyril and Methodius", 50 Divizija 6, 1000 Skopje, Republic of North Macedonia
| | - Kalina Gjorgjievska
- Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University "Ss. Cyril and Methodius", 50 Divizija 6, 1000 Skopje, Republic of North Macedonia
| | - Dimche Zafirov
- Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University "Ss. Cyril and Methodius", 50 Divizija 6, 1000 Skopje, Republic of North Macedonia
| | - Dragica Zendelovska
- Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University "Ss. Cyril and Methodius", 50 Divizija 6, 1000 Skopje, Republic of North Macedonia
| | - Marija Petrushevska
- Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University "Ss. Cyril and Methodius", 50 Divizija 6, 1000 Skopje, Republic of North Macedonia
| | - Nikola Labachevski
- Department of Preclinical and Clinical Pharmacology & Toxicology, Faculty of Medicine, University "Ss. Cyril and Methodius", 50 Divizija 6, 1000 Skopje, Republic of North Macedonia
| |
Collapse
|
2
|
Fan L, Zhang L, Zheng H, Cheng J, Hu Y, Liu J, Fan H. Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions. Clin Pharmacol Drug Dev 2020; 9:593-601. [PMID: 32413238 DOI: 10.1002/cpdd.765] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Accepted: 11/19/2019] [Indexed: 12/14/2022]
Abstract
To assess the bioequivalence of two 5-mg olanzapine orally disintegrating tablet (ODT) products, 2 randomized, open-label, single-dose, 2-way crossover studies were carried out under fasting or fed conditions. Blood samples were collected at scheduled times according to the study protocol. Statistical analysis of area under the concentration-time curve from time 0 to 168 hours (AUC0-t ), area under the curve from time zero to infinity (AUC0-∞ ), and peak plasma concentration (Cmax ) was conducted. Two formulations were considered bioequivalent if the 90% confidence intervals (CIs) of the geometric mean ratios for AUC0-t, AUC0-∞ , and Cmax were within the range of 0.80-1.25. Adverse events were recorded and evaluated throughout the studies. A total of 48 subjects with 24 in each study completed the 2 studies. In fasted subjects, the 90%CIs for the test product versus the reference product were 97.28%-105.13% for AUC0-t , 97.57%-105.54% for AUC0-∞ , and 90.94%-103.97% for Cmax . In fed subjects, the 90%CIs for AUC0-t , AUC0-∞ and Cmax were 99.73%-122.63%, 99.56%-121.75%, and 99.46%-120.46%, respectively. No serious adverse events were reported in the studies. The reference and the test product of 5-mg olanzapine ODT show comparable pharmacokinetic profiles under both fed and fasted conditions and were considered bioequivalent.
Collapse
Affiliation(s)
- Lin Fan
- Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.,School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
| | | | - Hongquan Zheng
- Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.,School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
| | - Junlin Cheng
- Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
| | - Yunfang Hu
- Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
| | - Jianghui Liu
- Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
| | - Hongwei Fan
- Department of Clinical Pharmacology Lab, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.,School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China
| |
Collapse
|
3
|
Yin A, Shang D, Wen Y, Li L, Zhou T, Lu W. Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis. Eur J Clin Pharmacol 2016; 72:933-44. [PMID: 27117554 DOI: 10.1007/s00228-016-2040-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2015] [Accepted: 03/02/2016] [Indexed: 11/29/2022]
Abstract
PURPOSE The aim of this study was to build an eligible population pharmacokinetic (PK) model for olanzapine in Chinese psychotic patients based on therapeutic drug monitoring (TDM) data, with assistance of meta-analysis, to facilitate individualized therapy. METHODS Population PK analysis for olanzapine was performed using NONMEM software (version 7.3.0). TDM data were collected from Guangzhou Brain Hospital (China). Because of the limitations of TDM data, model-based meta-analysis was performed to construct a structural model to assist the modeling of TDM data as prior estimates. After analyzing related covariates, a simulation was performed to predict concentrations for different types of patients under common dose regimens. RESULTS A two-compartment model with first-order absorption and elimination was developed for olanzapine oral tablets, based on 23 articles with 390 data points. The model was then applied to the TDM data. Gender and smoking habits were found to be significant covariates that influence the clearance of olanzapine. To achieve a blood concentration of 20 ng/mL (the lower boundary of the recommended therapeutic range), simulation results indicated that the dose regimen of olanzapine should be 5 mg BID (twice a day), ≥ 5 mg QD (every day) plus 10 mg QN (every night), or >10 mg BID for female nonsmokers, male nonsmokers and male smokers, respectively. CONCLUSION The population PK model, built using meta-analysis, could facilitate the modeling of TDM data collected from Chinese psychotic patients. The factors that significantly influence olanzapine disposition were determined and the final model could be used for individualized treatment.
Collapse
Affiliation(s)
- Anyue Yin
- School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.,Peking University/Pfizer Pharmacometrics Education Center, Peking University Health Science Center, Beijing, 100191, China.,State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, China
| | - Dewei Shang
- Guangzhou Brain Hospital (Guangzhou Huiai Hospital, the Affiliated Brain Hospital of Guangzhou Medical University), Guangzhou, 510370, China
| | - Yuguan Wen
- Guangzhou Brain Hospital (Guangzhou Huiai Hospital, the Affiliated Brain Hospital of Guangzhou Medical University), Guangzhou, 510370, China
| | - Liang Li
- School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.,Peking University/Pfizer Pharmacometrics Education Center, Peking University Health Science Center, Beijing, 100191, China.,State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, China
| | - Tianyan Zhou
- School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.,Peking University/Pfizer Pharmacometrics Education Center, Peking University Health Science Center, Beijing, 100191, China.,State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, China
| | - Wei Lu
- School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China. .,Peking University/Pfizer Pharmacometrics Education Center, Peking University Health Science Center, Beijing, 100191, China. .,State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, China. .,Beijing Institute for Brain Disorders, Beijing, 100088, China.
| |
Collapse
|
4
|
Cavalcanti Bedor NCT, Galindo Bedor DC, Miranda de Sousa CE, Nunes Bonifácio F, da Mota Castelo Branco D, Bastos Leal L, Pereira de Santana D. The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study. Clin Exp Pharmacol Physiol 2015; 42:305-13. [PMID: 25491375 DOI: 10.1111/1440-1681.12353] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Revised: 11/30/2014] [Accepted: 12/02/2014] [Indexed: 11/27/2022]
Abstract
1. A rapid method using liquid chromatography tandem mass spectrometry for the quantification of olanzapine (OLZ) in human plasma was developed and validated. Venlafaxine was used as the internal standard (IS), and the samples were extracted from 400-μL human plasma with methyl tert-butyl ether for liquid-liquid extraction. 2. Chromatography was performed using an ACE C18, 125 × 4.6-mm i.d., 5-μm column. The mobile phase consisted of water with 0.1% formic acid for solvent A and acetonitrile with 0.1% formic acid for solvent B (50 : 50 v/v) in isocratic mode. The flow rate was 1.2 mL/min. The retention times for OLZ and the IS were 0.78 and 1.04 min, respectively. Tandem mass spectrometry operating in positive electrospray ionization mode with multiple reaction monitoring was used to detect OLZ and the IS (m/z: 313.1 > 256.1 and 278.1 > 260.2, respectively). 3. No significant matrix effects were observed on OLZ and the IS retention times, and the mean recovery of OLZ was 90.08%. The assay was linear in the concentration range of 1-20 ng/mL (R(2) = 0.9976). The intra- and inter-day precision were < 11.60% and the accuracy was < 1.66%. 4. This validated method was successfully applied to a pharmacokinetic study in which 10-mg OLZ tablets were administered to healthy volunteers and their plasma OLZ levels were monitored over time. The tests showed that the OLZ test and reference drug (Zyprexa(®)) were bioequivalent, as 90% of the confidence intervals were within the 80-125% interval proposed by regulatory agencies.
Collapse
|